Drugs / Tolerogenic Fibroblasts
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05080270 | Sep 2020 → Jun 2021 | relapsing-remitting multiple sclerosis | FibroBiologics | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tolerogenic Fibroblasts | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05080270 ↗ |
| Modality | Cell therapy | “100 million tolerogenic fibroblasts” NCT05080270 ↗ |
| Route | Intravenous | “via intravenous infusion” NCT05080270 ↗ |